Result: In total, five mutations (
A67V,
E406E/G,
D427D/Y,
Q493R and
G1204G/E) appeared in the
S gene in samples taken from four patients (P2, P3, P5 and P6), three of whom were receiving bamlanivimab therapy (one as a monotherapy and two in combination) and one a combination of casirivimab/imdevimab.
Discussion: However, no rise of the viral load was observed between the two samples, and the patient recovered from
COVID-19, suggesting a limited impact of this mutation on immune escape and resistance, similar to the
G1204G/E mutation selected with bamlanivimab/etesevimab.